Intrance Medical Systems

Intrance Medical Systems, Inc., is a private, U.S.-based biopharmaceutical company focused on the development and commercialization of its lead clinical product for the treatment of advanced Parkinson’s disease in the U.S., Canada, South America, Japan and Taiwan. Intrance’s lead product, known as Lecigon® in the European market, is a fixed-dose combination treatment of levodopa, carbidopa and entacapone for enteral infusion in advanced Parkinson’s disease patients. The company is rapidly advancing its streamlined U.S. clinical development program in this target indication. Our team is comprised of industry veterans with extensive expertise in advanced Parkinson's disease including proven track records in regulatory, clinical development and commercialization. Intrance is backed by a strong syndicate of investors. The product, which was acquired by a neurology specialty pharma company for commercialization in Europe, has been rapidly gaining market share and user acceptance.